Preliminary results from a Phase II trial of EPO906 patients with advanced refractory ovarian cancer

被引：0

作者：

Kaye, S

Oza, A

Gore, M

Huinink, W

Smit, W

Gibbon, D

Miller, W

Mull, R

Chitale, K

Rothermel, J

机构：

[1] Royal Marsden Hosp, Dept Radiotherapy & Oncol, Sutton, Surrey, England

[2] Princess Margaret Hosp, Dept Med Oncol & Hemotol, Toronto, ON M4X 1K9, Canada

[3] Antoni Van Leeuwenhoek Ziekenhuis, Dept Med Oncol, Amsterdam, Netherlands

[4] Med Spectrum Twente, Dept Internal Med & Hemotol, Enschede, Netherlands

[5] Canc Inst New Jersey, New Brunswick, NJ USA

[6] Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ, Canada

[7] Novartis Pharmaceut, Oncol, E Hanover, NJ USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

127

引用

页码：S43 / S43

页数：1